Home/Pipeline/SHR-1701

SHR-1701

Non-small Cell Lung Cancer

Phase II/IIIActiveNCT05194384

Key Facts

Indication

Non-small Cell Lung Cancer

Phase

Phase II/III

Status

Active

Company

Jiangsu Hengrui Medicine

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine's mission is to advance healthcare through high-quality, innovative medicines, solidifying its position as China's largest and most valuable pharmaceutical company. Its key achievements include building a massive pipeline of 719 drug candidates, successfully launching multiple blockbuster oncology drugs in China, and establishing international R&D footprints. The company's strategy centers on aggressive investment in proprietary R&D, a dual-track approach of 'innovation + internationalization,' and dominating key therapeutic areas like oncology while expanding into metabolic, autoimmune, and neurological diseases.

View full company profile

Therapeutic Areas

Oncology Anesthesia Metabolic Disease Autoimmune Disease Cardiovascular

Other Non-small Cell Lung Cancer Drugs

Drug	Company	Phase	Status
CM24	Purple Biotech	Phase 2	Active
Pepinemab (VX15/2503)	Vaccinex	Phase 1b/2	Completed
GC-001	Genocury Biotech	Preclinical	Active
Immunomodulator Platform	OmniCyte	Research	Active
VisAcT (18F-AraG) Imaging in NSCLC	CellSight Technologies	Phase 2	Active
VNX-208	Vironexis Biotherapeutics	Preclinical	Active
AIC100	AffyImmune Therapeutics	Pre-clinical/Planned	Active
Lung (NSCLC) PD-L1	Mindpeak	Commercial	Active
Tiragolumab	Chugai Pharmaceutical	Phase III	Active
Acasunlimab (DuoBody-PD-L1x4-1BB)	Genmab	Phase 2/3	Active
VAC2	Lineage Cell Therapeutics	Phase 1	Active